nEPHroProtEction, Part oF MULti-orGan ProtEction

in hypertension study (LIFE): a randomised trial against atenolol.
Lancet 2002;359:995-1003.
29. Brewster UC, Perazella MA. Can dual blockade of the renin-angiotensin
system reduce progression of kidney disease beyond monotherapy?
Expert Opin Drug Safety 2004;3(1):9-23.
30. Campbell R, Samgalli F, Perticucci E. Effects of combined ACE
inhibitor and angiotensin II antagonist treatment in human chronic
nephropathies. Kidney Int 2003;63:1094-103.
31. Tylicki L, Larczynski W, Rutkowski B. Renal protective effects
of the renin-angiotensin-aldosterone system blockade: from
evidence-based approach to perspectives. Kidney Blood Press
2005;28(4):230-42.
32. Rossert J, Fouqueray B, Boffa JJ. Anemia management and the delay of
chronic renal failure progression. J Am Soc Nephrol 2003;14(S2):173-7.
33. Nakamura T, Ushiyama C, Hirokawa K, et al. Effect of cerivastatin on
urinary albumin excretion and plasma endothelin-1 concentrations
in type 2 diabetes patients with microalbuminuria and dyslipidemia.
Am J Nephrol 2001;21(6):449-54.
34. Zoja C, Corna D, Camozzi D, et al. How to fully protect the kidney in
a severe model of progressive nephropathy: a multidrug approach. J
Am Soc Nephrol 2002;13(12):2898-908.
35. Usui H, Shikata K, Matsuda M, et al. HMG-CoA reductase inhibitor
ameliorates diabetic nephropathy by its pleiotropic effects in rats.
Nephrol Dial Transplant 2003;18(2):265-72.
36. O’Donnell MP, Kasiske BL, Kim Y, et al. Lovastatin retards the
progression of established glomerular disease in obese Zucker rats.
Am J Kidney Dis 1993;22(1):83-9.
37. Grasso G, Sfacteria A, Cerami A, et al. Erythropoietin as a tissueprotective
cytokine in brain injury: what do we know and where do
we go? Neuroscientist 2004;10(2):93-8.
38. Wright GL, Hanlon P, Amin K, et al. Erythropoietin receptor
expression in adult rat cardiomyocytes is associated with an acute
cardioprotective effect for recombinant erythropoietin during
ischemia-reperfusion injury. FASEB J 2004;18(9):1031-3.
39. Hirata A, Minamino T, Asanuma H, et al. Erythropoietin just before
reperfusion reduces both lethal arrhythmias and infarct size via the
phosphatidylinositol-3 kinase-dependent pathway in canine hearts.
Cardiovasc Drugs Ther 2005;19(1):33-40.
40. Ehrenreich H, Hasselnlatt M, Dembowski C, et al. Erythropoietin
therapy for acute stroke is both safe and beneficial. Mol Med
2002;8:495-505.
41. Viviani B, Bartesaghi S, Corsini E, et al. Erythropoietin protects primary
hippocampal neurons increasing the expression of brain-derived
neurotrophic factor. J Neurochem 2005;93(2):412-21.
42. Rossert J, Eckardt KU. Eryrhropoietin receptors: their role beyond
erythropoiesis. Nephrol Dial Transplant 2005;20:1025-28.
43. Lauver DA, Booth EA, White AJ, et al. Sulodexide attenuates myocardial
ischemia/reperfusion injury and the deposition of C-reactive protein
in areas of infarction without affecting hemostasis. J Pharmacol Exp
Ther 2005;312(2):794-800.
44. Gambaro G, Kinalska I, Pont’uch P, et al. Oral sulodexide reduces
albuminuria in microalbuminuric and macroalbuminuric diabetic
patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 2002;
3:1615-25.
45. Gluhovschi Gh, Schiller A, Raica M, et al. The effects of the therapy
with natural glycosaminoglycans (Sulodexide) on proteinuria in
different types of glomerulonephritis. Facta Univ Series Medicine
and Biology (Nis, Yugoslavia) 2001;8(1):26-30.
_____________________________
Gheorghe Gluhovschi et al 197